Rezultati pretraživanja
  1. 12. pro 2019.

    I love seeing how our household's electricity is generated... 0% Coal 0% Nuclear Get . It doesn't cost the Earth 🌍🙂

  2. 5. pro 2019.

    Why do the director sell shares just 2 days before the crucial data release for the company ? Brian S Posner, Director of has sold $308,429 worth of stock on 12/3

  3. 12. pro 2019.
  4. 18. pro 2019.

    It's a beautiful morning on the Inner Harbor 🙂 I'm off to Johns Hopkins in a couple hours for dose #4 in the trial.

  5. Osobe Vidi sve

  6. 5. pro 2019.
  7. After disappointing trial results, will discontinue development of gosuranemab for PSP and other primary tauopathies.

  8. 14. sij
  9. prije 3 sata

    A warm welcome to Team First Move🚵‍♀️ - now proudly powered by 🙌 and have competed at the highest level - they know what it takes to 👏 Read more about team First Move 👇

  10. prije 1 sat

    in Uptrend: RSI indicator enters overbought zone. View odds for this and other indicators:

  11. 28. stu 2019.

    Thank you to for hosting the Meeting of the Minds. Partnerships with such great organizations is what allows Biogen to bring forward innovative solutions for people living with neurological diseases. Together let’s help those who need it most.

  12. 24. stu 2019.

    🔥 showdown Thurs Dec 5🔥 Same day presents Phase 3 data, Dr. Jeffrey Cummings presents Phase 3 cognition sub-study data.

    Prikaži ovu nit
  13. prije 6 sati

    Don’t miss out on all the action LIVE 👇 Who will be victorious in this year’s 👀😁 Powered by 💯

  14. lucrative mode! Exited half on both! WINS MYLANS CHALLENGE TO PATENT ON TECFIDERA

  15. Did Biogen (BIIB) just find a cure? This stock is up massively.

  16. 4. velj

    ! Best of luck and best regards! Check out with a visit while in Boston!

  17. reports earnings: EPS: $8.34 (adj.) Revenue: $3.671B

  18. 29. sij

    The MOST hopeful news! FDA Gives Biogen Green Light to Relaunch Aducanumab Study on Trial Participants - Being Patient

  19. 28. sij

    The FDA has given the green light to relaunch a clinical trial for , its drug. The company said today it expects past trial participants to start receiving the drug again as early as March. Read more here:

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.